- I'll be debuting Axios' Audience Bill of Rights & Manifesto alongside other Axios reporters today at our inaugural Town Hall event, Axios' War for Truth. RSVP here.
Today's word count is 1,212, or a 5-minute read.
Today's word count is 1,212, or a 5-minute read.
The U.S. is now averaging nearly 250,000 new coronavirus cases per day — a crisis of staggering proportions, even though many Americans have tuned it out, Axios' Sam Baker and Andrew Witherspoon report.
The big picture: It's not even sufficient to say the pandemic is “still going on." The pandemic is raging. Its deadliest and most dangerous days are happening right now. And it keeps getting worse.
Everywhere you look, day-to-day vigilance is fading.
But as Americans are taking the virus less seriously, it is becoming more serious.
What's next: This will keep getting worse before it gets better.
Hospitals around the country remain filled beyond capacity, threatening the quality of care provided both to coronavirus patients and people suffering other medical emergencies.
Why it matters: We're beginning to see more than 4,000 coronavirus deaths a day, and heart attacks and car accidents are still happening, whether or not the local hospital has any room left.
Zoom in: Officials in Los Angeles County, where beds have been set up in hallways and patients wait hours in ambulances to be admitted to the emergency room, per the L.A. Times , said yesterday that hospitals likely haven't seen the effects of the end of the holiday season.
The bottom line: Vaccines may be the dominant story in the news right now, but the situation on the ground is still dire.
Illustration: Sarah Grillo/Axios
A seemingly more transmissible coronavirus variant is threatening the world — and exposing the U.S.' lackluster genetic surveillance, Axios' Bryan Walsh reports.
Why it matters: A beefed-up program to sequence the genomes of infectious disease pathogens infections could help the U.S. identify dangerous new coronavirus variants — and get the jump on pathogens that could ignite the pandemics of the future.
Driving the news: New variants of SARS-CoV-2 are being identified by scientists around the world, Axios' Marisa Fernandez reports.
Yes, but: Genetic surveillance of coronavirus variants in the U.S. lags well behind dozens of other countries, which means we lack a clear picture of exactly how the novel coronavirus currently infecting more than 200,000 people a day is mutating here.
Be smart: The bottleneck here isn't scientific. Genetic sequencing has gotten faster and cheaper, and every state in the U.S. has the technical capacity to decode viral genomes.
More than 100 pharmaceutical companies raised prices on over 600 drugs at the beginning of the new year, according to a new report from the advocacy group Patients for Affordable Drugs.
The big picture: Millions of people have lost their health insurance because of the pandemic, and uninsured patients must often pay the full sticker price for prescription drugs, Axios' Marisa Fernandez writes.
By the numbers: 95% of price hikes were on brand-name drugs. The median increase was about 5%, and almost all of them were greater than inflation.
The other side: As drugmakers are always quick to note, list prices don't tell the full story. Patients with insurance don't pay those prices, and may not see any increase in their costs even when list prices go up.
Participants who received Johnson & Johnson's one-shot vaccine in an early study developed immunity to the coronavirus for at least 71 days, but the company's production lag could mean a rollout of fewer-than-promised doses, the New York Times reported Wednesday.
Why it matters: If approved, J&J's vaccine would be the first available to protect from COVID with a single dose, streamlining vaccine administration and distribution, Axios' Shawna Chen writes.
The big picture: The U.S. government signed a $1 billion contract with J&J last August. The drug company promised that 12 million doses of its vaccine would be ready for deployment by the end of this February and a total of 100 million doses by the end of June.
The good news: J&J's vaccine doesn't require freezing like Moderna and Pfizer-BioNTech's shots, per Bloomberg, and can be stored at refrigerator temperatures for three months.
What to watch: Results from a late-stage trial of 45,000 volunteers will offer more data in the coming weeks, but the company anticipates a high efficacy rate at or above 70%, chief scientific officer Paul Stoffels told Bloomberg.
Illustration: Aïda Amer/Axios
Coronavirus deaths have risen by 10% or more since last week in 25 states, and yesterday was the third time national deaths rose above 4,000, per the Covid Tracking Project.
Thanks largely to social distancing and mask-wearing — as well as higher uptake of the flu vaccine — influenza deaths this season are almost nonexistent, Bryan reports.
Some of the most prominent sources of coronavirus misinformation were part of the mob that stormed the Capitol last week, NYT reports.
Some states are pushing for students and teachers to return to classrooms as teachers gain access to the coronavirus vaccine, AP reports.
Dollar General is offering to pay its workers to get a coronavirus vaccine, becoming one of the first large U.S. employers to incentivize employees to be vaccinated, WSJ reports.